WOCKPHARMA Wockhardt Q4 FY26 results (Jan–Mar 2026) and concall
Wockhardt reported strong financial performance for FY26, driven by significant revenue and EBITDA growth, and a substantial improvement in EBITDA margin. The company achieved a landmark US FDA approval for its novel antibiotic, Zaynich, and outlined ambitious global launch plans. While anticipating initial profitability pressure from new business investments, management expressed confidence in long-term growth and continued focus on antibiotic research.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q4 FY26: revenue up 29.9%, net profit up 464.4% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|
| Revenue | 809 | 721 | 743 | 738 | 782 −3% | 888 +23% | 965 +30% |
| EBITDA | 110 | 128 | 64 | 72 | 178 +62% | 177 +38% | 225 +252% |
| Net profit | -16 | 20 | -45 | -108 | 82 +613% | 61 +205% | 164 +464% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
